One in every of Bristol-Myers Squibb Co.’s largest shareholders is opposing the corporate’s $74 billion deal to purchase rival Celgene Corp., changing into the newest investor to precise its unhappiness with the transaction.

READ  The constructive mindset of traders

Wellington Administration Co., an funding agency that has a stake of about 8% in Bristol-Myers, mentioned Wednesday the deal asks shareholders to tackle an excessive amount of danger and provides Bristol shares too cheaply to Celgene shareholders. The agency additionally mentioned executing a profitable transaction might be harder than administration has anticipated….

READ  No, you may't undertake the alligator discovered on this N.J. pond


Please enter your comment!
Please enter your name here